Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee: SGLT-2 Inhibitors and Diabetic Ketoacidosis

Basic Details
Date
Thursday, January 17, 2019
Medical Product
canagliflozin
dapagliflozin
empagliflozin
sitagliptin
sodium-glucose cotransporter-2 (SGLT-2) inhibitor
Health Outcome(s)
diabetic ketoacidosis